Healthcare

Market estimates ahead of the report called for earnings of $1.36 per share on revenue of $1.15 billion. Before the move, the stock had closed at $271.04 on Oct. 26 and was up about 0.6% that day, with a 52-week high of $309.35.

INVO Fertility acquires, builds and operates fertility clinics in the United States, and also sells its INVOcell device, used in an intravaginal culture procedure, to outside clinics. It runs four operating clinics, after buying the remaining interests in its Birmingham, Alabama site in June.

The stock closed at $2.80 on October 23, down 13.31% that day, with a 52-week range of $2.33 to $18.40. Today's price is below that low, extending a decline in which the stock has fallen far from its 52-week high.

On the same day, Acumen Pharmaceuticals (NASDAQ:ABOS) reported that its Phase 2 ALTITUDE-AD study of sabirnetug, an antibody aimed at toxic amyloid beta oligomers, missed its primary endpoint at both doses. ProMIS's lead candidate also targets toxic amyloid beta oligomers, though any link between …

GAAP dilutedEarnings Per Sharewere $18.45, up 35%, and non-GAAPDiluted Earnings per Sharewere $20.07, up 70%.GAAPNet Incomerose 33% to $1.95 billion. Collaboration revenue from Sanofi (NASDAQ:SNY) grew 68%, helped by a higher profit share on antibody sales and full repayment of the Sanofi development balance.

Acumen, based in Newton, Massachusetts, is a clinical-stage biopharmaceutical company developing antibodies that target toxic soluble amyloidBetaoligomers. Sabirnetug, also known as ACU193, was its lead candidate and was dosed by infusion every four weeks in the 542-participant study.

The FDA accepted Agios' supplemental application for mitapivat in sickle cell disease under Priority Review for accelerated approval, with a goal date of November 1, 2026. Agios develops therapies for rare diseases built around pyruvate kinase activators, and mitapivat is already approved for pyruvate …